Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

Seeking Alpha's Quant system consistently outperforms the S&P 500 ( SP500 ), driven by powerful computer processing and SA's ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

Eli Lilly has expanded a collaboration with ... against rivals such as Apple and FitBit whose wearable devices have an increasing medical focus with tech like ECG readers. ActiGraph provides ...

After years of preparation, Eli Lilly is on the ... and can link with compatible devices. That includes continuous glucose monitoring systems developed by Lilly's partner Dexcom as well as other ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

and delivering life-changing medicines to address some of the world's most pressing medical needs. With a market cap of $759.4 billion, Eli Lilly operates across diverse therapeutic areas ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...